Navigation Links
Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012
Date:5/7/2012

MARLBOROUGH, Mass., May 7, 2012 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces that its technology will be highlighted both as part of the scientific sessions and during a private academic symposium at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, May 9-12 in Boston, MA. The presentations will feature clinical experiences and outcomes using the company's technology, the first visually-guided laser balloon ablation system.

"We are pleased that over two years of comprehensive clinical experiences with our technology will be featured at this prominent industry conference. Many of the leading international experts in heart rhythm management will be participating in these sessions and presenting their own findings with the HeartLight EAS, and we anticipate engaging discussion on the applicability of the system in clinical practice," said Stephen Sagon, President and CEO of CardioFocus.

During the scientific sessions, the presentation "Worldwide Experience Using the Endoscopic Ablation System for Ablation of Atrial Fibrillation" will give an overview of the feasibility and safety of AF ablation using the HeartLight EAS, with findings representing the first patients treated with the technology by 32 different operators across 19 medical centers. The presentation will be made by Boris Schmidt, MD, of Cardioangiologisches Centrum Bethanien, Frankfurt, Germany on Friday, May 11 at 3:25 p.m. ET.

The HeartLight EAS Symposium, to be held the evening of Thursday, May 10 at the Renaissance Boston Waterfront Hotel, will feature presentations from cardiology thought leaders on the evolution of pulmonary vein (PV) isolation ablation, the adoption of the new visually-guided laser balloon ablation technique, and the clinical experiences with the technology at centers throughout Europe. It will be chaired by Prof. Petr Neuzil, MD, of Na Homolce Hospital, Prague, Czech Republic and Prof. Thorsten Lewalter, MD, of Isar Heart Center, Munich, Germany.

The HeartLight EAS is a unique catheter ablation technology that incorporates an endoscope for direct visualization of the inside of the heart and a compliant, dynamically adjustable balloon catheter designed for improved contact with the PV ostium irrespective of the individual patient anatomy. It also utilizes laser energy for more efficient, durable and precise ablation treatment. 

The system is available in Europe for the treatment of AF, and is currently the focus of a pivotal trial in the U.S. For more information, please visit the CardioFocus booth #1103 or www.CardioFocus.com.

About CardioFocus, Inc.CardioFocus, Inc. is a medical device manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF). Its novel HeartLight® Endoscopic Ablation System for catheter ablation incorporates an endoscope to provide physicians with the capacity to see within the heart, and for the first time, visually direct the application of laser energy to achieve durable pulmonary vein isolation.

The HeartLight Endoscopic Ablation System is commercially available at leading institutions throughout Europe. The device is investigational in the U.S., and currently the focus of a pivotal trial initiated in 2012. CardioFocus is headquartered in Marlborough, MA, USA.  For more information on the company and its technology, please visit www.CardioFocus.com.

The scientific information discussed in this news release is preliminary and investigative. The CardioFocus HeartLight Endoscopic Ablation System is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the system. Only FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Healthcare professionals should refer to/rely upon FDA-approved labeling for the products, and not the information discussed in this news release.Company Contact:

Media Contact:Anjie Roldan

Lisa CookVice President Finance

(646) 536-7012(508) 658-7237

lcook@theruthgroup.com aroldan@cardiofocus.com
'/>"/>

SOURCE CardioFocus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Telemedicine Monitoring: Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018
2. ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report
3. Leading Pharma Events CPhI Worldwide, ICSE, P-MEC Europe & InnoPack to Return to Frankfurt in 2013 after Record Breaking Year
4. Prometheus Signs Research & Collaboration Agreement with Leading Worldwide Pharmaceutical Company
5. Cardica Achieves Key Milestone With Over 25,000 PAS-Port® Proximal Anastomosis Systems Deployed Worldwide
6. UH Case Medical Center the First in Region to Enroll Patients in Worldwide Study
7. Thermogenesis Signs Worldwide Res-Q System Distribution Agreement With Arthrex for Sports Medicine Applications
8. The Outlook for Medical Devices Worldwide
9. The Outlook for Pharmaceuticals Worldwide
10. BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine
11. Medical Centers Worldwide Adopt Both Accurays CyberKnife and TomoTherapy Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... -- The global peripheral I.V. catheter market accounted for ... to grow at a CAGR of 6.0% during 2016-2022. ... share in the global market between the two types ... hospital segment accounted for the highest share in the ... I.V. catheter market is witnessing high growth rate, due ...
(Date:1/23/2017)... , Jan. 23, 2017  HOPE BIOSCIENCES ... rights to develop and commercialize nuc -gemcitabine™ ... a Korean pharmaceutical company. nuc ... aptamer against surface nucleolin found on many cancer ... Unlike ADCs (antibody drug conjugates) or SMDCs (small ...
(Date:1/23/2017)... 23, 2017  Based on its recent analysis ... recognizes Ansell, a global leader in protection solutions, ... of the Year Award. Ansell,s comprehensive product portfolio, ... global footprint have placed it in a position ... The Company,s established product line and robust innovation ...
Breaking Medicine Technology:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... Sharon Kleyne, ... the air to educate listeners about the benefits of making new water infrastructure a ... Kleyne said, “it’s appropriate that we expect water infrastructure to become a top priority ...
(Date:1/23/2017)... Indiana (PRWEB) , ... January 23, 2017 , ... ... Center for Assisted Living (IHCA/INCAL), will serve as a healthcare industry expert at ... 23. The panel discussion, moderated by Inside Indiana Business host Gerry Dick, will ...
(Date:1/23/2017)... ... January 23, 2017 , ... Moisture measurement ... the right method is paramount to success. Selecting an inappropriate measurement method can ... multiple persons use the same equipment. Rare or expensive substances are wasted and ...
(Date:1/23/2017)... Viejo, California (PRWEB) , ... January 23, 2017 , ... "ProRandom is a set of ... camera to create dynamic looks in Final Cut Pro X," said Christina Austin - CEO ... of up to two layers of text with video footage. ProRandom works by using ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... (OREF), in partnership with the American Society of Anesthesiologists® (ASA®), the Foundation ... the American Academy of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages ...
Breaking Medicine News(10 mins):